Home / About LSDs / Batten Disease (NCL)
Batten Disease (NCL): Types, Symptoms and Treatment in India
Batten disease is the common name for a group of rare inherited disorders, the neuronal ceroid lipofuscinoses (NCLs), in which waste material builds up in nerve cells. It usually begins in childhood, with seizures, loss of skills and loss of vision. One type, CLN2 disease, now has an approved enzyme treatment.
Key facts
Cause
Changes in one of more than a dozen CLN genes, such as TPP1 (CLN2) and PPT1 (CLN1)
Inheritance
Mostly autosomal recessive
Mainly affects
Brain and eyes
In India
CLN2 disease is the type diagnosed most often
Treatment
Enzyme replacement therapy for CLN2 disease; supportive care for other types
On this page:
Overview
What is Batten disease?
Batten disease is the common name for the neuronal ceroid lipofuscinoses (NCLs), a group of more than a dozen rare genetic disorders. In each, a change in a different gene stops the lysosomes in cells from clearing away waste properly.
A fatty, protein-rich material called lipofuscin builds up inside cells, especially nerve cells in the brain and the light-sensing cells of the eye. Over time, these cells stop working and die.
This causes seizures, loss of vision, and a gradual loss of skills such as walking, talking and thinking. Most types begin in childhood. Doctors name each type after the gene involved, from CLN1 to CLN14.
Why early diagnosis matters
For CLN2 disease, time matters
Enzyme replacement therapy can slow the loss of walking and other skills in CLN2 disease, and works best when started early. If a young child has new seizures together with delayed speech, especially between 2 and 4 years of age, ask the doctor about testing for CLN2 disease.
Batten disease in India
Studies from Indian hospitals suggest that CLN2 disease is the type diagnosed most often in India, followed by types such as CLN1, CLN6, CLN7 and CLN8. In one study of 50 children in Karnataka, nearly half had CLN2 disease.
Neuronal ceroid lipofuscinosis is on the list of rare diseases under the National Policy for Rare Diseases 2021. Marriage between close relatives (consanguinity) raises the chance of inherited conditions like Batten disease. Carrier testing and genetic counselling help families understand their risk.
Did you know?
In Indian studies, CLN2 disease is the most commonly diagnosed type of Batten disease.
It is also the only type with an approved enzyme treatment, so finding out the exact type matters.
Types of Batten disease
Each type is caused by a different gene and is named after it. Some types are also known by the age at which symptoms usually begin.
CLN1 disease (infantile)
Caused by changes in the PPT1 gene. Symptoms usually begin between 6 and 24 months of age, with slowing development, seizures, vision loss and a rapid loss of skills. People with milder gene changes can develop symptoms later.
CLN2 disease (late-infantile)
Caused by changes in the TPP1 gene. Delayed speech and seizures usually begin between 2 and 4 years of age, followed by loss of walking, speech and vision. It can be treated with enzyme replacement therapy.
CLN3 disease (juvenile)
Caused by changes in the CLN3 gene. The first sign is usually a rapid loss of vision between 4 and 7 years of age, followed by seizures, learning difficulties, and problems with movement and behaviour.
CLN5, CLN6, CLN7, CLN8 and other types
Several other types usually begin in early or later childhood, with seizures, loss of skills and loss of vision. In India, CLN6, CLN7 and CLN8 are among the types found most often after CLN2 and CLN1. Rare adult-onset types also exist.
Signs and symptoms
Symptoms of Batten disease
Symptoms depend on the type and usually get worse over time. They may include:
- Seizures (fits), often the first sign of CLN2 disease
- Slowing development, or loss of skills already learned, such as walking and talking
- Gradual loss of vision, often the first sign of CLN3 disease
- Clumsiness, unsteady walking and jerky movements
- Changes in behaviour, mood and sleep
- Problems with learning, memory and thinking
When to see a doctor
Consult a doctor, ideally a paediatric neurologist, if your child has:
- New seizures, especially after a period of normal development
- Delayed speech together with seizures
- Loss of skills already learned
- Unexplained loss of vision at school age
An eye examination and an EEG (a test of the brain’s electrical activity) can give early clues, and a blood test can check for CLN1 and CLN2 disease.
Causes
What causes Batten disease?
Batten disease is caused by changes (mutations) in one of more than a dozen genes. Some of these genes make enzymes, such as tripeptidyl peptidase 1 (TPP1) in CLN2 disease and palmitoyl-protein thioesterase 1 (PPT1) in CLN1 disease. Others make proteins whose exact role is still being studied.
When the protein is missing or does not work, waste material builds up in the lysosomes of cells, especially in the brain and eyes.
How it is inherited
- Most types are inherited in an autosomal recessive pattern.
- Parents of an affected child are usually healthy carriers of one faulty copy of the gene.
- When both parents are carriers, each pregnancy has a 1 in 4 (25%) chance of an affected child.
- One rare adult-onset type can be inherited from just one parent.
- Genetic counselling and carrier testing can help families understand their risk and plan.
How is Batten disease diagnosed?
Blood tests and genetic tests can confirm Batten disease and its type.
01
Enzyme test
A blood test, often on a dried blood spot, measures the enzymes TPP1 and PPT1. Low TPP1 activity points to CLN2 disease, and low PPT1 activity to CLN1 disease.
02
Genetic test
A gene panel or exome test finds the gene involved and confirms the type. It also helps test family members and plan future pregnancies.
03
EEG and brain MRI
An EEG records the brain’s electrical activity and can show patterns typical of some types. A brain MRI shows changes in the brain.
04
Eye examination
An eye doctor can look for changes in the retina, and special tests check how well the retina is working.
Treatment for Batten disease
One type, CLN2 disease, has an approved enzyme replacement therapy. For the other types, care focuses on managing symptoms and quality of life.
Enzyme replacement therapy for CLN2 disease
Cerliponase alfa (Brineura®) replaces the missing TPP1 enzyme. It is given into the fluid around the brain, through a small device placed under the scalp, every two weeks. It can slow the loss of walking and other skills, and works best when started early.
Approval
- Approved in the United States and Europe in 2017
- Since 2024, approved in the United States for children of all ages, including before symptoms begin
- We are not aware of approval for sale in India; ask your doctor or Centre of Excellence about access
Supportive care
A team of specialists helps manage symptoms as the disease progresses.
This can include
- Medicines to control seizures
- Physiotherapy, and help with movement and posture
- Feeding support, including feeding tubes
- Support for vision loss, learning and behaviour
Palliative care, family support and research
Palliative care focuses on comfort and quality of life for the child and the whole family, and can be given alongside other care. Gene therapies and other treatments for several types are being studied in clinical trials. See the list of studies recruiting in India below.
Genetic counselling is an important part of care. Brothers and sisters of a child with CLN2 disease can be tested early, because treatment works best before skills are lost.
Clinical trials and studies in India
Studies of Batten disease that are recruiting, or about to recruit, in India. This list updates automatically every day.
There are no studies of Batten disease recruiting in India at the moment. This list is checked every day, so new studies will appear here automatically.
Last checked 8 November 2026 on ClinicalTrials.gov. Always talk to your doctor before joining a study.
Accessing treatment in India
Getting treatment and support in India
Caring for a child with Batten disease is demanding, emotionally and financially. These are the main sources of help.
Government support (NPRD)
Neuronal ceroid lipofuscinosis is on the list of rare diseases under the National Policy for Rare Diseases (NPRD) 2021. Ask your nearest Centre of Excellence (COE) what support is available, including financial assistance of up to ₹50 lakh for eligible patients.
- Visit your nearest COE with all medical reports
- Ask about genetic counselling and testing for the family
- Financial assistance is subject to approval
Other sources of help
- State government health schemes
- Corporate social responsibility (CSR) funding
- Crowdfunding through the government rare disease portal
- Palliative care services near you
How LSDSS helps
- Connects patients with COEs and specialists
- Guides families through funding applications
- Shares updates on support programmes
- Brings patients and caregivers together
Frequently asked questions
Answers to common questions about Batten disease.
Still have a question?
Batten disease is the common name for the neuronal ceroid lipofuscinoses (NCLs), a group of rare inherited disorders in which waste material builds up in nerve cells, causing seizures, loss of vision and a gradual loss of skills.
Each type is named after the gene involved, from CLN1 to CLN14. In India, CLN2 (late-infantile) disease is diagnosed most often, followed by types such as CLN1, CLN6, CLN7 and CLN8. CLN3 (juvenile) disease is the most common type in some other countries.
For CLN2 disease, enzyme replacement therapy with cerliponase alfa can slow the loss of skills. There is no approved disease-specific treatment for the other types yet, but supportive care helps, and new therapies are being tested in clinical trials.
We are not aware of it being approved for sale in India. In some cases, doctors can apply to import a medicine for an individual patient. Talk to your doctor or nearest Centre of Excellence, and contact us for guidance.
Most types are autosomal recessive: a child is affected when both parents pass on a faulty copy of the gene. When both parents are carriers, each pregnancy has a 1 in 4 chance of an affected child.
It depends on the type. The infantile and late-infantile types usually shorten life to childhood, while people with the juvenile type often live into early adulthood. Treatment for CLN2 disease and good supportive care can make a difference.
First, visit your nearest Centre of Excellence (COE) with all medical reports to be evaluated and to get genetic counselling. Second, register with LSDSS for support and to connect with other families.
Other lysosomal storage disorders
LSDSS supports patients and families living with all lysosomal storage disorders.
A fatty substance builds up in nerve cells of the brain and spinal cord.
Sulfatides build up and damage the protective covering of nerves.
A fatty substance builds up in nerve cells and, in babies, in other organs and bones.
Caring for a child with Batten disease?
Register with LSDSS for guidance, support and the latest updates. You are not alone.
This page is for general information and awareness only. It does not replace advice from a qualified doctor. Last reviewed: November 2026.